Stock AnalizOmeros Corp. OMER
Biotechnology: Pharmaceutical Preparations · IPO 2009 · data as of November 13, 2026
Omeros Corp. (OMER) is a healthcare company listed in the US with a market value of about $1.3B. In the twelve months to June 30, 2026 it had revenue of $38M and net income of $125M, a net margin of 324.9%.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 14.5, a 5-year average ROIC of -186%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 87% below the current price.
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $38M | — | — | — | — | — | $74M | $112M | $30M | $65M | $42M |
| Net income | $125M | -$3M | -$157M | -$118M | $47M | $194M | -$138M | -$84M | -$127M | -$53M | -$67M |
| Free cash flow | -$69M | -$116M | -$149M | $74M | -$87M | -$110M | -$100M | -$60M | -$104M | -$37M | -$52M |
| EPS (diluted) | $1.72 | $-0.05 | $-2.70 | $-1.88 | $0.76 | $3.12 | $-2.41 | $-1.71 | $-2.61 | $-1.17 | $-1.65 |
| Net margin | 324.9% | — | — | — | — | — | -187.0% | -75.6% | -424.4% | -82.5% | -160.4% |
| ROIC | — | — | -581.7% | -78.3% | -38.3% | -46.8% | -94.5% | -156.6% | -204.8% | -53.7% | -126.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $27.50, 57% above the current price; targets range from $22.00 to $33.00; the consensus rating is “none”; expected EPS is $0.69 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Omeros’s P/E ratio?
About 14.5, based on the last twelve months of diluted earnings per share (forward P/E about 26.5).
Is Omeros stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 87% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Omeros pay a dividend?
Not currently.
Is Omeros a good stock to buy?
We do not give buy or sell advice. Omeros scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.